Development of a Quantitative Systems Pharmacology Model to Explore Hemostatic Equivalency of Antithrombin Lowering

抗凝血酶 药理学 医学 抗凝血酶 止血 重症监护医学 肝素 内科学
作者
Chanchala D. Kaddi,Mengdi Tao,Randolph J. Leiser,Ane Miren Salvador,Sravya Kattula,Pratik R. Bhagunde,Viridiana Cano Garcia,Ekta Seth Chhabra,Susana R. Neves
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 5606-5607 被引量:5
标识
DOI:10.1182/blood-2022-169043
摘要

Fitusiran is an investigational siRNA therapeutic that targets antithrombin (AT) to rebalance hemostasis in people with hemophilia A (PwHA) or B (PwHB), irrespective of inhibitor status. Phase 3 clinical studies have demonstrated that fitusiran prophylaxis significantly reduced bleeding events compared to on-demand or prophylaxis treatment with factor concentrates or bypassing agents (Srivastava et al. Blood 2021; Young et al. Blood 2021; Kenet et al. ISTH 2022). To better understand the hemostatic equivalency of fitusiran prophylaxis (i.e., AT lowering), a quantitative systems pharmacology (QSP) model was developed to investigate thrombin generation in PwHA and PwHB in the context of AT lowering. QSP modeling is a mechanistic approach that integrates clinical and nonclinical data of the coagulation pathway to simulate the results of multiple in vitro coagulation assays, including the thrombin generation assay (TGA) and to mechanistically understand the readouts of these assays. The QSP model builds on prior published models of the coagulation cascade (Attarwala et al. ISTH 2017; Sridharan et al. Blood 2017), updated to represent reported steady-state levels of coagulation factors and accessory proteins in the plasma of healthy individuals and PwHA and PwHB (Figure 1). In addition, the model was extended to describe the impact of α-2-macroglobulin, a key regulator of thrombin, with increased influence at reduced AT levels that is critical to understand the impact of fitusiran on thrombin generation (Kattula et al. Blood 2020). After representing coagulation dynamics from plasma from healthy individuals, PwHA, and PwHB, the QSP model was applied to simulate TGA and relevant metrics, including thrombin peak height (Figure 1). TGA simulations were performed across different percentages of AT and FVIII. These simulations reproduced experimental TGA data from AT- and FVIII-double depleted plasma that was spiked with different levels of AT and/or FVIII. For these in vitro experiments, Factor VIII (FVIII) and AT-double depleted plasma was generated from congenital FVIII-deficient plasma by immunodepleting AT using an anti-AT antibody and recombinant AT protein was spiked back in to achieve different levels of AT. The QSP simulations also reproduced the reported formation of α-2-macroglobulin complexes with thrombin in each condition. Subsequently, the model was validated using both internal and published TGA and activated partial thromboplastin time (aPTT) datasets that were not used during model development. Next, a large (n=1000) virtual population (VP) of severe PwHA (<1% FVIII) was generated based on calibration of the model to individual patient data from completed fitusiran clinical studies. This analysis considered individual patient pharmacokinetic and AT time courses to describe thrombin peak height associated with different levels of AT reduction from fitusiran prophylaxis within a representative population of severe PwHA. The target therapeutic AT range of fitusiran prophylaxis treatment at steady state is 15-35%. Based on this model, the peak thrombin generated at 15-35% AT was similar to peak thrombin observed at 10-20 IU/kg FVIII in PwHA. In summary, by considering the impact of α-2-macroglobulin, the QSP model provides a mechanistic representation of thrombin generation under conditions of AT lowering, consistent with internal TGA data from donor-derived spiked plasma and clinical TGA data from both PwHA and PwHB. The VP analysis of fitusiran prophylaxis provided hemostatic equivalency with FVIII in a representative population of severe PwHA, with a targeted therapeutic range of AT of 15-35% resulting in a thrombin peak profile which was comparable to 10-20 IU/kg FVIII. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhou发布了新的文献求助10
刚刚
刚刚
科研通AI6.3的应助被冰冰采纳,获得10
1秒前
1秒前
1秒前
fq完成签到 ,获得积分10
2秒前
3秒前
小马甲的应助被wms采纳,获得10
3秒前
HWX完成签到,获得积分10
4秒前
4秒前
炸薯条完成签到,获得积分10
5秒前
凡人修仙完成签到,获得积分10
5秒前
桐桐的应助被乔清采纳,获得10
5秒前
XIAOJU_U完成签到 ,获得积分10
6秒前
Aster_Caelus发布了新的文献求助10
7秒前
妖妖灵1111发布了新的文献求助10
7秒前
7秒前
Akim的应助被GBY采纳,获得10
9秒前
xi发布了新的文献求助10
9秒前
11秒前
公鸡下蛋发布了新的文献求助10
11秒前
daisylili完成签到,获得积分10
11秒前
12秒前
12秒前
大胆蛋挞发布了新的文献求助10
12秒前
Zzzyam完成签到,获得积分10
12秒前
jcz完成签到,获得积分10
14秒前
14秒前
15秒前
15秒前
wanghongyue发布了新的文献求助10
16秒前
Sylvia发布了新的文献求助10
16秒前
daisylili发布了新的文献求助10
17秒前
小二郎的应助被大胆绿柳采纳,获得10
18秒前
乔清发布了新的文献求助10
19秒前
汉堡包的应助被邢智翔采纳,获得10
20秒前
梦M完成签到,获得积分10
20秒前
彭于晏的应助被比山稳采纳,获得10
21秒前
21秒前
感动书蝶完成签到 ,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177901
求助须知:如何正确求助?哪些是违规求助? 9568676
关于积分的说明 21800345
捐赠科研通 7772540
什么是DOI,文献DOI怎么找? 3432548
关于科研通互助平台的介绍 2556720
邀请新用户注册赠送积分活动 2478085